Followers | 43 |
Posts | 4255 |
Boards Moderated | 0 |
Alias Born | 07/14/2010 |
Thursday, April 08, 2021 12:06:55 PM
IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.
Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%
Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%
Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600
Balance Sheet
Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71
Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
Recent IMMP News
- Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma • GlobeNewswire Inc. • 05/02/2024 12:00:00 PM
- Immutep Quarterly Activities Report Q3 FY24 • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Immutep Announces First Clinical Data from 90mg Dosing of Efti • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 09:01:56 PM
- Immutep Quarterly Activities Report Q2 FY24 • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 11:06:56 AM
- Immutep Receives A$2.6 million R&D Tax Incentive from French Government • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial • GlobeNewswire Inc. • 11/22/2023 01:00:00 PM
- Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer • GlobeNewswire Inc. • 11/06/2023 01:00:00 PM
- Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 10:06:58 AM
- Immutep to Participate in November Investor Events • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Immutep Quarterly Activities Report Q1 FY24 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Immutep receives ~A$1.13 million R&D Tax Incentive • GlobeNewswire Inc. • 10/25/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/25/2023 10:07:25 AM
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/24/2023 10:35:30 AM
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- Immutep Announces Publication of Abstracts at ESMO Congress 2023 • GlobeNewswire Inc. • 10/16/2023 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM